CA2130563A1 - 2,6-Methano-2H-Quinolizin Derivative as 5-HT3-Receptor Antagonist - Google Patents

2,6-Methano-2H-Quinolizin Derivative as 5-HT3-Receptor Antagonist

Info

Publication number
CA2130563A1
CA2130563A1 CA 2130563 CA2130563A CA2130563A1 CA 2130563 A1 CA2130563 A1 CA 2130563A1 CA 2130563 CA2130563 CA 2130563 CA 2130563 A CA2130563 A CA 2130563A CA 2130563 A1 CA2130563 A1 CA 2130563A1
Authority
CA
Canada
Prior art keywords
treatment
quinolizin
receptor antagonist
methano
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2130563
Other languages
French (fr)
Other versions
CA2130563C (en
Inventor
Maurice W. Gittos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2130563A1 publication Critical patent/CA2130563A1/en
Application granted granted Critical
Publication of CA2130563C publication Critical patent/CA2130563C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to 5-chloro-2, 3-dihydro-2,2-dimethylbenzofuran-7-carboxylic acid-octahydro-3-hydroxy-2,6-metha-no-2H-quinolizin-8-yl ester (I), a novel 5-HT3-receptor antagonist, its method of preparation, and to its end-use application in the treatment of radio- and chemo-therapeutically-induced nausea and vomiting, in the treatment of pain associated with migraine, in the treatment of cognitive disorders, in treating hallucinatory endogenous psychoses of the type manifested in patients suffering from schizophrenia and mania, for irritable bowel syndrome, and to combat drug abuse.
CA002130563A 1992-02-24 1993-02-03 2,6-methano-2h-quinolizin derivative as 5-ht3-receptor antagonist Expired - Lifetime CA2130563C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP92400474.0 1992-02-24
EP92400474 1992-02-24

Publications (2)

Publication Number Publication Date
CA2130563A1 true CA2130563A1 (en) 1993-09-02
CA2130563C CA2130563C (en) 1997-11-11

Family

ID=8211614

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002130563A Expired - Lifetime CA2130563C (en) 1992-02-24 1993-02-03 2,6-methano-2h-quinolizin derivative as 5-ht3-receptor antagonist

Country Status (14)

Country Link
EP (1) EP0628043A1 (en)
JP (1) JPH07504192A (en)
KR (1) KR100287933B1 (en)
AU (1) AU675060B2 (en)
CA (1) CA2130563C (en)
FI (1) FI105917B (en)
HU (1) HU216831B (en)
IL (1) IL104821A (en)
MX (1) MX9300948A (en)
NO (1) NO943101D0 (en)
NZ (1) NZ249346A (en)
TW (1) TW226374B (en)
WO (1) WO1993017019A1 (en)
ZA (1) ZA931146B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2672500A (en) 1999-02-18 2000-09-04 Novartis Ag Systemic use of 5-ht3 receptor antagonists against rheumatic inflammatory processes
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
MX2007010833A (en) 2005-03-07 2009-02-17 Univ Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration.
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68924545T2 (en) * 1988-02-23 1996-03-21 Merrell Dow Pharma Use of quinolizine and quinolizone derivatives for the manufacture of medicaments.
EP0517984A1 (en) * 1991-06-11 1992-12-16 Merrell Dow Pharmaceuticals Inc. Derivatives of amide analogs of certain methano bridged quinolizines

Also Published As

Publication number Publication date
EP0628043A1 (en) 1994-12-14
WO1993017019A1 (en) 1993-09-02
AU675060B2 (en) 1997-01-23
FI943872A (en) 1994-08-23
NO943101L (en) 1994-08-23
MX9300948A (en) 1993-08-01
CA2130563C (en) 1997-11-11
HU9402436D0 (en) 1994-10-28
HU216831B (en) 1999-09-28
KR950700297A (en) 1995-01-16
IL104821A0 (en) 1993-06-10
KR100287933B1 (en) 2001-05-02
HUT68249A (en) 1995-06-28
FI105917B (en) 2000-10-31
JPH07504192A (en) 1995-05-11
NZ249346A (en) 1995-10-26
TW226374B (en) 1994-07-11
NO943101D0 (en) 1994-08-23
AU3603493A (en) 1993-09-13
FI943872A0 (en) 1994-08-23
IL104821A (en) 1997-01-10
ZA931146B (en) 1993-09-14

Similar Documents

Publication Publication Date Title
SI0725779T1 (en)
WO2000035919A3 (en) Quinoline derivatives
CA2149242A1 (en) Quinuclidine Derivative for Treatment of Inflammatory and Gastrointestinal Disorders
CA2182981A1 (en) Sublingual or buccal pharmaceutical composition
HUP9701096A3 (en) Use of benzenesulfonamides for the preparation of pharmaceutical compositions treating disorders of the central nervous system, novel derivatives, process for their preparation and pharmaceutical compositions containing them
IE891798L (en) Novel ó-glucosidase inhibitors
EP0884319A3 (en) [1,3]oxazino[3,2-A]indole derivative
ZA941542B (en) Heterocyclic compounds their use and preparation
AU1877495A (en) Naphthylamides as central nervous system agents
UA70919C2 (en) Composition for treating and preventing arterial thrombosis based on selective inhibitors of factor xa alone or in combination with compounds possessing anti-platelet aggregation activity
CA2094702A1 (en) Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents
EP1032556A4 (en) Pharmaceutically active compounds and methods of use
CA2139385A1 (en) Products containing g-csf and tnf binding protein
WO1996023769A3 (en) Heterocyclic compounds possessing 5ht2c receptor antagonist activity
WO1998026770A3 (en) The topical use of kappa opioid agonists to treat ocular pain
CA2130563A1 (en) 2,6-Methano-2H-Quinolizin Derivative as 5-HT3-Receptor Antagonist
AU6428294A (en) Imidazoloquinoxalinone derivatives as eaa antagonists
HU9201799D0 (en) New 2-amino-5-ciano-1,4-dihydropiridine-derivatives, process for their use and their use as medicaments
CA2235951A1 (en) Novel uses of mammalian ctla-8 and related reagents
WO2000006575A3 (en) Azabicyclic compounds
CA2269031A1 (en) Treatment of urinary incontinence and compositions for use therein
CA2149766A1 (en) Rectal flunisolide compositions for treating inflammatory intestinal disorders
AU686976B2 (en) Isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1, 4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate
CA2180155A1 (en) Naphthylamides as central nervous system agents
WO1999015160A3 (en) Use of 6,7-substituted 2-aminotetralines suitable for preparing pharmaceutical composition for the therapeutic treatment of inflammatory and/or autoimmune pathologies

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20130204

MKEX Expiry

Effective date: 20130204